PHOTO
Cairo, Egypt : Siemens Healthineers, a leader in healthcare imaging and diagnostic technology, is showcasing a variety of its cutting-edge laboratory diagnostic portfolios at the EGY Health International Congress and Exhibition taking place on September 7-9, 2021, in the Egyptian International Exhibition Center (EIEC).
“Industry events, such as EGY Health, that convene an impressive depth and breadth of stakeholders from across the medical field are crucial to the mission of Siemens Healthineers,” said Michael Schmermer, Managing Director Siemens Healthineers - Egypt, Djibouti, Eretria, Sudan, and Libya. “We know that strong partnerships improve access to healthcare. We look forward to strengthening our existing partnerships and creating new business relationships as we continue to drive innovation to help humans live healthier and longer.”
Siemens Healthineers is not only featuring innovative products from several portfolios at the event but is also presenting during the Congress. On Sept. 9th, Eng. Mohamed Gharib, Automation & Diagnostics IT Business Manager, Middle East and Africa at Siemens Healthineers will be speaking on the topic of lab digitalization and workflow excellence.
Throughout the three-day event, Siemens Healthineers will be showcasing some of it laboratory diagnostic solutions such as Covid-19 portfolio: FTD SARS COV 2, Clinitest Covid-19 AG rapid test, and SARS COV 2 antibody (Total & IgG); the Atellica portfolio: Atellica Solution, Atellica Neph 630, and Atellica Hematology; the Hemostasis portfolio; the POC portfolio, the Atellica VTLI, Atellica DCA, and the Atellica Urine.
Siemens Healthineers is a leading medical technology company with over 120 years of experience, 18,500 patents globally, and over 50,000 employees in more than 70 countries. An estimated five million patients worldwide everyday benefit from the company’s innovative technologies and services in the areas of diagnostic and therapeutic imaging, laboratory diagnostics and molecular medicine as well as digital health and enterprise services.
-Ends-
About Siemens Healthineers
Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare.
Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology.
These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care to patients.
In fiscal 2020, which ended on September 30, 2020, Siemens Healthineers generated revenue of €14.5 billion and adjusted EBIT of €2.2 billion. Following the acquisition of Varian Medical Systems, Inc. the company has approximately 66,000 employees worldwide. Further information is available at www.siemens-healthineers.com.
For further information, please contact:
Engy Emad
Senior Media Relations Manage
TRACCS Egypt
Mobile: 010 0900 2207
Email: engy.emad@traccs.net
For media inquiries, please contact: Ansam Amin , Country Head for Marketing and Communications Egypt
Email : ansam.amin@siemens-healthineers.com
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
